Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Expression changes in arrestin β 1 and genetic variation in catechol-O-methyltransferase are biomarkers for the response to morphine treatment in cancer patients.

Oncology reports - 1 May 2012

Matsuoka Hiromichi, Arao Tokuzo, Makimura Chihiro, Takeda Masayuki, Kiyota Hidemi, Tsurutani Junji, Fujita Yoshihiko, Matsumoto Kazuko, Kimura Hideharu, Otsuka Masatomo, Koyama Atsuko, Imamura Chiyo K, Tanigawara Yusuke, Yamanaka Takeharu, Tanaka Kyoko, Nishio Kazuto, Nakagawa Kazuhiko

Abstract excerpt

Genetic differences in individuals with regard to opioid-receptor signaling create clinical difficulties for opioid treatment; consequently, useful pharmacodynamic and predictive biomarkers are needed. In this prospective study, we studied gene expression changes in peripheral blood leukocytes using a microarray and real-time RT-PCR analysis to identify...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Analgesics, Opioid
Share to Arrestins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to beta-Arrestins

Share to Biomarkers

Share to Catechol O-Methyltransferase

Share to Gene Expression Regulation, Neoplastic

Share to Morphine

Share to Neoplasms

Source

Identifiers

PMID: 22293824
DOI: 10.3892/or.2012.1660

Genes

COMT
ARRB1
OPRM1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Expression changes in arrestin β 1 and genetic variation in catechol-O-methyltransferase are biomarkers for the response to morphine treatment in cancer patients.PMID 22293824Read ↗

Association Between Human Pain-Related Genotypes and Variability in Opioid Analgesia: An Updated Review.Semantic proximity Read ↗

Exploring joint effects of genes and the clinical efficacy of morphine for cancer pain: OPRM1 and COMT gene.Semantic proximity Read ↗

Clinical Implications of Opioid Pharmacogenomics in Patients With Cancer.Semantic proximity Read ↗

Pharmacogenomics and Patient Treatment Parameters to Opioid Treatment in Chronic Pain: A Focus on Morphine, Oxycodone, Tramadol, and Fentanyl.Semantic proximity Read ↗

Pain polymorphisms and opioids: An evidence based reviewSemantic proximity Read ↗

OPRM1 influence on and effectiveness of an individualized treatment plan for prescription opioid use disorder patients.Semantic proximity Read ↗

Pharmacogenomics and Morphine.Semantic proximity Read ↗

Pain and genetics.Semantic proximity Read ↗

OPRM1 c.118A>G Polymorphism and Duration of Morphine Treatment Associated with Morphine Doses and Quality-of-Life in Palliative Cancer Pain Settings.Semantic proximity Read ↗

Variations in critical morphine biosynthesis genes and their potential to influence human health.Semantic proximity Read ↗

Pain management in the 21st century: utilization of pharmacogenomics and therapeutic drug monitoring.Semantic proximity Read ↗

Prospective replication study implicates the catechol-O-methyltransferase Val158Met polymorphism as a biomarker for the response to morphine in patients with cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.